Ten years into its quest to validate a novel targeted drug delivery technology, Beijing-based Innolife is looking to bring a heart failure drug candidate into Phase III development to demonstrate the molecule’s ability to repair damaged cardiac tissue.
China’s Innolife Bets On Heart Failure Drug With Novel Mechanism
Beijing-based Innolife claims that its drug candidate INL1 can deliver trace elements directly to damaged cardiac tissue. The targeted approach is aimed at activating HIF-1, a protein crucial for growth and oxygen supply and which can promote tissue repair.
